I agree—in more ways than one. I thought the PR was unusually disingenuous even by biotech standards.
To date, this hasn’t been seen with ALX-0081/0681, although these programs are still very early.
My overall assessment of Ablynx is that is has some buyout vig, but not much else to make it attractive for investing. The main problem is competition: there are manifold companies developing small antibody-like drugs, and hence there’s a high probability that one or more of these techniques will prove to be better than nanobodies. Investing in Ablynx is (IMO) tantamount to a bet that some Big Pharma buys them out before it becomes common knowledge that another company’s platform is superior. This is not necessarily a bad bet, but it’s not a bet I’m inclined to make.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.